glp-1 agonist and heart failure Glucagon-like peptide 1 receptor agonists: cardiovascular benefits mechanisms of action GLP-1 receptor agonists and cardiovascular

However, unlike GLP-1R agonists, DPP-4 inhibitors do not cause significant reductions in body weight (Meneghini et al., 2011

In the 2023 guidelines, the ADA emphasizes both supporting higher weight loss and focusing on obesity as a chronic disease

For instance, a retrospective study revealed that SGLT2i reduced incidence of HHF and acute kidney injury [72]

86,87 These pathways are proposed to support brain health during aging by reducing neuroinflammation and promoting synaptic plasticity and neurogenesis

95.Sacks F.M., Bray G.A., Carey V.J., Smith S.R., Ryan D.H., Anton S.D., McManus K., Champagne C.M., Bishop L.M., Laranjo N., et al

A recent study indicated a consistent increase in prescriptions for obesity management medications in the United States, rising from 0.76 to 0.80 million between July 2017 and June 2018 and from 1.29 to 1.51 million between March 2023 and February 2024